T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Nature

Volumn 545, Issue 7652, 2017, Pages 60-65

  Huang, Alexander C ^a,b,c   Postow, Michael A ^d,e   Orlowski, Robert J ^a,b,c   Mick, Rosemarie ^a,b,c   Bengsch, Bertram ^b,c   Manne, Sasikanth ^b   Xu, Wei ^a   Harmon, Shannon ^a   Giles, Josephine R ^b,c   Wenz, Brandon ^a   Adamow, Matthew ^d   Kuk, Deborah ^d   Panageas, Katherine S ^d   Carrera, Cristina ^d,f   Wong, Phillip ^d   Quagliarello, Felix ^b   Wubbenhorst, Bradley ^a   D'Andrea, Kurt ^a   Pauken, Kristen E ^b   Herati, Ramin S ^a,b   Staupe, Ryan P ^b   Schenkel, Jason M ^g   McGettigan, Suzanne ^a   Kothari, Shawn ^a   George, Sangeeth M ^b,c   Vonderheide, Robert H ^a,b,c   Amaravadi, Ravi K ^a   Karakousis, Giorgos C ^a,b   Schuchter, Lynn M ^a   Xu, Xiaowei ^a,b   Nathanson, Katherine L ^a,c   Wolchok, Jedd D ^d   Gangadhar, Tara C ^a   Wherry, E John ^a,b,c   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF BARCELONA   (Spain)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ANTIBODY; BLOOD; CANCER; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; HEMATOLOGY; IMMUNE RESPONSE; PHYSIOLOGY; TUMOR;

ARTICLE; BLOOD; CANCER PATIENT; CANCER STAGING; CELL CLONE; CLINICAL OUTCOME; DONOR; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; MELANOMA; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOLOGY; FEMALE; IMMUNOLOGY; MALE; METABOLISM; PATHOLOGY; TREATMENT OUTCOME; VASCULARIZATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MELANOMA; NEOPLASM STAGING; PHENOTYPE; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 85017451727     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature22079     Document Type: Article

References (32)

1. Topalian, S. L., Taube, J. M., Anders, R. A., Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275-287 (2016).
2. Fridman, W. H., Pagès, F., Sautès-Fridman, C., Galon, J. The immune contexture in human tumours: Impact on clinical outcome. Nat. Rev. Cancer 12, 298-306 (2012).
3. Herbst, R. S., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
4. Tumeh, P. C., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
5. Pauken, K. E., Wherry, E. J. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 36, 265-276 (2015).
6. Barber, D. L., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2006).
7. Topalian, S. L., Drake, C. G., Pardoll, D. M. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 27, 450-461 (2015).
8. Robert, C., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521-2532 (2015).
9. Ribas, A., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol. 16, 908-918 (2015).
10. Blackburn, S. D., et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10, 29-37 (2009).
11. Twyman-Saint Victor, C., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373-377 (2015).
12. Brahmer, J. R., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010).
13. Paley, M. A., et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338, 1220-1225 (2012).
14. Im, S. J., et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417-421 (2016).
15. He, R., et al. Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection. Nature 537, 412-416 (2016).
16. Bengsch, B., et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog. 6, e1000947 (2010).
17. Duraiswamy, J., et al. Phenotype, function, gene expression profiles of programmed death-1hi CD8 T cells in healthy human adults. J. Immunol. 186, 4200-4212 (2011).
18. Gupta, P. K., et al. CD39 expression identifies terminally exhausted CD8+ T cells. PLoS Pathog. 11, e1005177 (2015).
19. Pauken, K. E., et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354, 1160-1165 (2016).
20. Gros, A., et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat. Med. 22, 433-438 (2016).
21. Miller, J. D., et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28, 710-722 (2008).
22. Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R., Ahmed, R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77, 4911-4927 (2003).
23. Wilmott, J. S., et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 18, 1386-1394 (2012).
24. Knight, D. A., et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Invest. 123, 1371-1381 (2013).
25. Balch, C. M., et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199-6206 (2009).
26. Rizvi, N. A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
27. Sharma, P., Allison, J. P. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 161, 205-214 (2015).
28. Smyth, M. J., Ngiow, S. F., Ribas, A., Teng, M. W. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat. Rev. Clin. Oncol. 13, 143-158 (2016).
29. Nishino, M., et al. Developing a common language for tumor response to immunotherapy: Immune-related response criteria using unidimensional measurements. Clin. Cancer Res. 19, 3936-3943 (2013).
30. Wolchok, J. D., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
31. Breiman, L. Random Forests. Mach. Learn. 45, 5-32 (2001).
32. Qiu, P., et al. Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat. Biotechnol. 29, 886-891 (2011).